The subject invention provides materials and methods for producing, isolating, extracting and purifying single-molecule products. The subject invention provides materials and methods for extracting microbial metabolites at a high level of purity, for example, a purity of at least 80% by weight, and preferably at least 95% by weight or more. Specifically, the subject invention provides materials and methods for isolating or extracting biosurfactants and polyketides at a high level of purity. Preferably, the biosurfactant is a sophorolipid (SLP).

The subject invention provides materials and methods for producing, isolating, extracting and purifying single-molecule products. The subject invention provides materials and methods for extracting microbial metabolites at a high level of purity, for example, a purity of at least 80% by weight, and preferably at least 95% by weight or more. Specifically, the subject invention provides materials and methods for isolating or extracting biosurfactants and polyketides at a high level of purity. Preferably, the biosurfactant is a sophorolipid (SLP).

The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.

The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.

Systems, methods and computer-readable media are provided for designing experiments for organisms at a first scale to generate first-scale performance data used in predicting performance of the organisms at a second, larger scale. The design includes determining first-scale screening conditions based at least in part upon the contribution of second-scale conditions to performance parameters of an organism at the second scale. The first-scale screening conditions include one or more proxies for second-scale conditions that cannot be replicated at first scale. The design determines first-scale screening parameters based at least in part upon computer modeling of the metabolism of the organism at the second scale.

The present disclosure provides a spiramycin-producing strain, a carrimycin-producing strain, construction method therefor, use thereof and method for increasing the product yield thereof. The provided spiramycin-producing strain has an inactivated gene Lrp (Δlrp-SP); and the strain has a preservation number of CGMCC No.16056. The provided carrimycin-producing strain has an inactivated gene Lrp (Δlrp-BT); and the strain has a preservation number of CGMCC No.16055. By inactivating the gene Lrp, the yields of spiramycin and carrimycin are increased; and particularly the yield and proportion of a major component of the carrimycin, that is, 4″-O-isovalerylspiramycin III are significantly increased.

The present disclosure provides a spiramycin-producing strain, a carrimycin-producing strain, construction method therefor, use thereof and method for increasing the product yield thereof. The provided spiramycin-producing strain has an inactivated gene Lrp (Δlrp-SP); and the strain has a preservation number of CGMCC No.16056. The provided carrimycin-producing strain has an inactivated gene Lrp (Δlrp-BT); and the strain has a preservation number of CGMCC No.16055. By inactivating the gene Lrp, the yields of spiramycin and carrimycin are increased; and particularly the yield and proportion of a major component of the carrimycin, that is, 4″-O-isovalerylspiramycin III are significantly increased.

The present invention relates to a soluble dimeric fusion protein comprising a first and second polypeptides, wherein the first and second polypeptides each comprises a Dectin-1 receptor polypeptide fused to a human Fc domain via a dimerization linker. Methods of using the soluble dimeric fusion protein for immunizing a subject against a fungal infection, preventing or treating a fungal infection in a subject and detecting a fungal infection in a subject are also provided. In one embodiment, a chimeric molecule comprising the fusion protein and a payload is provided. In one embodiment, the payload is Amphotericin B.

Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.

Disclosed are methods of preparing everninomicin analogs by genetic alteration of Micromonospora carbonacea. Everninomicin analogs prepared by these methods and methods of using these analogs to treat infections are also disclose.